4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
PuraPharm Corporation Limited (1498) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Tai Po, Hong Kong with about 407 employees. Its market capitalization is roughly HKD 150 million. In the fiscal year ended 2025-12-31, 1498 reported HKD 336M in revenue and (HKD 35M) in net income.
PuraPharm Corporation Limited, an investment holding company, engages in research, development, production, and sale of concentrated Chinese medicine granule (CCMG) and Chinese healthcare products in Hong Kong, Mainland China, and internationally.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | HKD 336M | HKD 382M | HKD 407M | HKD 448M | — |
| Gross Profit | HKD 180M | HKD 205M | HKD 217M | HKD 263M | — |
| Operating Income (EBIT) | (HKD 22M) | (HKD 17M) | (HKD 37M) | (HKD 44M) | — |
| Net Income | (HKD 35M) | (HKD 35M) | (HKD 106M) | (HKD 120M) | — |
HKD; HKDM / HKDB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | HKD 694M | HKD 716M | HKD 844M | HKD 1.0B | — |
| Total Liabilities | HKD 563M | HKD 604M | HKD 691M | HKD 758M | — |
HKD; HKDM / HKDB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 1498 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms